ONESOURCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
OneSource Specialty Pharma has re-uploaded its audited standalone and consolidated financial results for Q4 and FY ended March 31, 2025 because the original scanned signature page of the Auditor's Report was unclear. The company confirms there are no changes to the figures previously submitted. The accompanying results show a dramatic turnaround: standalone revenue from operations jumped to Rs 1,299.59 crore in FY25 from Rs 171.92 crore in FY24, driven by the merger of CDMO and Soft Gelatin businesses from Strides Pharma and Steriscience via a scheme of arrangement effective April 1, 2024. Q4 FY25 standalone profit was Rs 174.88 crore versus a Rs 40.01 crore loss in Q4 FY24, and FY25 profit was Rs 20 crore versus a Rs 364.93 crore loss in FY24. The board also approved consolidation of Singapore subsidiaries and full redemption of 20,000 listed NCDs on November 28, 2024.
This is primarily an administrative re-filing with no change in numbers, so no immediate price impact. However, the underlying results reveal a substantial business turnaround and successful listing of the merged CDMO business on BSE/NSE in January 2025. Shareholders should note the going-concern flag: current liabilities exceeded current assets by Rs 45.6 crore as of March 31, 2025, though management cites new CDMO contracts and the scheme benefits as supportive.